Tumor-infiltrating Lymphocytes(H. Lee Moffitt Cancer Center and Research Institute)(Tumor-infiltrating Lymphocytes(H. Lee Moffitt Cancer Center and Research Institute)) - 药物靶点：CD40L_在研适应症：晚期非小细胞肺癌，转移性非小细胞肺癌，复发性非小细胞肺癌_专利_临床

概要

基本信息

药物类型

肿瘤浸润淋巴细胞

别名

CD40L TIL(H. Lee Moffitt Cancer Center and Research Institute)

靶点

CD40L

作用方式

刺激剂

作用机制

CD40L刺激剂(CD40配体刺激剂)、免疫细胞毒性、T淋巴细胞替代物

治疗领域

肿瘤呼吸系统疾病泌尿生殖系统疾病

在研适应症

晚期非小细胞肺癌转移性非小细胞肺癌复发性非小细胞肺癌+ [2]

非在研适应症-

原研机构

H. Lee Moffitt Cancer Center & Research Institute, Inc.

在研机构

H. Lee Moffitt Cancer Center & Research Institute, Inc.

非在研机构-

最高研发阶段临床1/2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

3

项与 Tumor-infiltrating Lymphocytes(H. Lee Moffitt Cancer Center and Research Institute) 相关的临床试验

NCT05768347

/ Recruiting临床1期IIT

Phase 1 Clinical Trial of Intravesical Adoptive Cell Therapy {ACT) With Tumor Infiltrating Lymphocytes (TIL) for Patients With BCG Exposed High Grade Non-Muscle Invasive Bladder Cancer (NMIBC)

The purpose of the study is to evaluate the feasibility, safety and tolerability of intravesical adoptive cell therapy using TIL (tumor infiltrating lymphocytes) in participants with urothelial cell carcinoma (UCC) non-muscle invasive bladder cancer (NMIBC).

开始日期2023-08-10

申办/合作机构

H. Lee Moffitt Cancer Center & Research Institute, Inc.

[+1]

NCT05681780

/ Recruiting临床1/2期IIT

Clinical Trial of CD40L-augmented Tumor Infiltrating Lymphocytes (CD40L TIL) for Patients With Oncogene-Driven Advanced Non-Small Cell Lung Cancer (NSCLC)

To determine the effect of a special preparation of cells, called tumor-infiltrating lymphocytes (TIL) stimulated with CD40L, when given with the drug nivolumab, for patients with EGFR, ALK, ROS1, or HER2-genomically altered lung cancer.

开始日期2023-03-10

申办/合作机构

H. Lee Moffitt Cancer Center & Research Institute, Inc.

NCT03215810

/ Completed临床1期IIT

A Phase I Clinical Trial Combining Nivolumab and Tumor Infiltrating Lymphocytes (TIL) for Patients With Advanced Non-Small Cell Lung Cancer

Investigators plan to study the safety, side effects, and benefits of tumor-infiltrating lymphocytes (TILs) when they are given with the drug nivolumab. Nivolumab is a type of immunotherapy - a drug that is used to boost the ability of the immune system to fight cancer, infection, and other diseases.

开始日期2017-10-11

申办/合作机构

H. Lee Moffitt Cancer Center & Research Institute, Inc.

[+4]

100 项与 Tumor-infiltrating Lymphocytes(H. Lee Moffitt Cancer Center and Research Institute) 相关的临床结果

登录后查看更多信息

100 项与 Tumor-infiltrating Lymphocytes(H. Lee Moffitt Cancer Center and Research Institute) 相关的转化医学

登录后查看更多信息

100 项与 Tumor-infiltrating Lymphocytes(H. Lee Moffitt Cancer Center and Research Institute) 相关的专利（医药）

登录后查看更多信息

100 项与 Tumor-infiltrating Lymphocytes(H. Lee Moffitt Cancer Center and Research Institute) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
晚期非小细胞肺癌	临床2期	美国	H. Lee Moffitt Cancer Center & Research Institute, Inc.	2023-03-10
转移性非小细胞肺癌	临床2期	美国	H. Lee Moffitt Cancer Center & Research Institute, Inc.	2023-03-10
复发性非小细胞肺癌	临床2期	美国	H. Lee Moffitt Cancer Center & Research Institute, Inc.	2023-03-10
非肌层浸润性膀胱肿瘤	临床1期	美国	H. Lee Moffitt Cancer Center & Research Institute, Inc.	2023-08-10
膀胱尿路上皮癌	临床1期	美国	H. Lee Moffitt Cancer Center & Research Institute, Inc.	2023-08-10

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ESMO2024	N/A	不可切除的黑色素瘤	102	Tumor Infiltrating Lymphocytes (TIL)	鑰獵餘窪艱簾醖鹽醖積(夢膚鑰艱衊選選蓋膚顧) = ICI-related toxicity was identified in 22 patients (24%), and among those 6 patients (27%) had a recurrence of a toxicity seen with pre-TIL ICI 膚糧衊鏇膚夢齋獵襯選 (網襯積製艱襯範積願顧 ) 更多	不佳	2024-09-14
ESMO2024	N/A	不可切除的黑色素瘤	102	Immune Checkpoint Inhibitor (ICI) Rechallenge		不佳	2024-09-14
SITC2022	N/A	非小细胞肺癌 PD-1+ \| IFN-Î³	103	tumor-infiltrating lymphocytes (Initial Expansion (IE) TILs)	廠構顧膚衊糧顧製憲衊(壓願積壓觸壓廠夢齋範) = 簾顧獵鏇鬱獵窪壓窪壓憲簾獵範選鏇艱遞齋襯 (夢網簾顧積餘築壓壓鑰, 0.02 ~ 30.8) 更多	积极	2022-11-07
SITC2022	N/A	非小细胞肺癌 PD-1+ \| IFN-Î³	103	tumor-infiltrating lymphocytes (Rapid Expansion (REP) TILs)	廠齋餘廠廠製鬱觸選鹽(獵餘壓構餘顧鏇觸鹽鑰) = 襯壓醖繭夢襯範襯淵糧鏇鹽網糧積鏇齋積蓋壓 (淵衊網膚遞醖窪廠鬱齋 ) 更多	积极	2022-11-07
SITC2016	临床2期	黑色素瘤	-	TIL therapy	夢淵鹹選鑰築網襯鹽遞(範範窪獵壓範鬱淵鹹夢) = 糧膚鏇鹹襯糧壓顧蓋選窪積壓網鏇鹽廠壓願構 (觸淵襯繭遞願廠積簾廠 )	积极	2016-11-16
SITC2014	临床1期	胰腺癌 mesothelin \| survivin \| NY-ESO-1	16	IL-2/IL-15/IL-21-expanded TIL	淵艱壓艱顧醖鏇淵糧獵(簾蓋遞顧醖鹽壓構構鬱) = 1/16 TIL cultures exhibited exclusively CD4+ TIL with a CD45RA-CCR7+ phenotype 願築獵選構築鏇顧選鹽 (壓顧憲艱鑰範顧網鬱鬱 ) 更多	-	2014-11-06
ASCO2014	临床2期	转移性黑色素瘤	56	Tumor-infiltrating lymphocytes (TIL)	鑰築鑰鹹壓鬱獵鏇願齋(積願夢壓糧繭繭艱積築) = 顧艱壓繭網鏇獵蓋築願顧壓夢積膚築鹹獵築襯 (廠獵廠艱網網齋鬱鹹膚 )	积极	2014-05-20